Kewin Injection contains Menadione Sodium Bisulfite 10mg as its active ingredient and is indicated for the treatment and prevention of vitamin K deficiency. Menadione, a synthetic form of vitamin K, plays a crucial role in the synthesis of clotting factors II, VII, IX, and X, which are essential for normal blood coagulation. Kewin Injection is primarily used in clinical settings to manage hemorrhagic disease of the newborn, vitamin K deficiency bleeding, and to counteract the effects of anticoagulant overdose, such as warfarin toxicity. The injectable formulation allows for rapid onset of action, making it suitable for urgent correction of coagulopathies. It is administered via intramuscular or intravenous routes under medical supervision. Caution is advised in patients with known hypersensitivity to menadione or bisulfite compounds. Adverse reactions are rare but may include hypersensitivity reactions, hemolytic anemia in susceptible individuals, and local injection site reactions. Dosage and administration should be tailored to the patient’s clinical condition and response to therapy. Kewin Injection should be stored at controlled room temperature, protected from light, and used according to established medical guidelines to ensure efficacy and safety.